semaglutide
Tirzepatide vs Semaglutide FDA Bulk Exclusion Explained
Tirzepatide vs Semaglutide FDA Bulk Exclusion Explained The FDA’s bulk exclusion rule means pharmacies can no longer compound tirzepatide or semaglutide in large-volume (503B) preparations; each prescription must be filled as an individually manufactured product. This change targets safety concerns around compounded GLP-1 drugs and reshapes how weight-loss and